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6/j.bThirty-one patients treated with mesenchymal stromal cells (MSCs) for acute graft-versus-host disease
(aGVHD) or hemorrhagic cystitis between 2002 and 2007 were followed to investigate predictors of out-
come, immunologic effects in vivo, and long-term survival. Therewas no correlation between in vitro suppres-
sion by MSCs in mixed lymphocyte cultures and outcome. Soluble IL-2 receptors were measured in blood
before and after MSC infusion and declined significantly during the first week after MSC infusion (P 5 .03).
Levels of interleukin-6 and HLA-G were unaffected. Infectious complications occurred several years after re-
covery from aGVHD.Cytomegalovirus viral loadwas high, and cytomegalovirus diseasewas common. Among
patients recovering from aGVHD, 54% died of late infections, between 4months and 2 years after MSC treat-
ment. No increase in leukemia relapse or graft rejection was found. Children had a better survival rate than
adults (P 5 .005). In GVHD patients, 1-year survival was 75% in patients who received early-passage MSCs
(from passages 1-2) in contrast to 21% using later passage MSCs (from passages 3-4) (P\.01). We conclude
that treatment with early-passage MSCs improved survival in patients with therapy-resistant GVHD. Death
from infection was common in MSC-treated patients, but there was no increase in leukemia relapse.
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Mesenchymal stroma cells (MSCs) are pluripotent
cells found in the bone marrow [1,2], and they have the
capacity to differentiate into mesenchymal lineages
including bone, cartilage, and fat [1-3]. MSCs are
immunomodulatory in vitro, suppress lymphocyte
alloreactivity in mixed lymphocyte cultures (MLCs)
[4,5], and have shown promising results in pilot
studies for the treatment of acute graft-versus-host dis-atology Centre, Department of Clinical Immunol-
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bmt.2011.07.023ease (aGVHD) [6] and tissue toxicity [7] following al-
logeneic hematopoietic stem cell transplantation.
MSCs modulate most cells of the immune system,
and questions have been raised regarding safety, with
1 report of increased leukemia relapse afterMSC treat-
ment [8]. There is concern that MSCs might further
increase the risk of infections, especially in severely
immunosuppressed patients suffering from aGVHD
where infection-related mortality rates are already
high. In vitro,MSCs do not affect antiviral lymphocyte
cytotoxicity [5], but very few clinical results have been
published.
We treated 31 patients with MSCs for GVHD and
hemorrhagic cystitis (HC), and we have previously re-
ported the short-term results [6,7,9]. We subsequently
wanted to evaluate the possibility of predicting
outcome for individual patients through in vitro
analysis before MSC treatment and whether other
factors in patient or MSC characteristics affected the
outcome. We also wanted to know the in vivo
immunologic effects of MSC therapy. In addition, we
wanted to investigate the long-term effects of MSC
therapy in terms of infectious complications, leukemia
relapse, and overall survival (OS).557
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Patients and MSCs
Patients treated with MSC for aGVHD (n 5 23)
and HC (n5 8) between 2002 and 2007 were included
in a retrospective study (Table 1). These patients rep-
resent the majority of patients with steroid-refractory
GVHD in our clinic during this period.
In the GVHD group, 5 patients had received more
than first-line GVHD treatment before MSC treat-
ment. One received mycophenolate mofetil, 1 siroli-
mus, and 3 infliximab plus daclizumab, in combination
with photopheresis in 1 case. In theHCgroup, no other
immunosuppressive agents were used before MSC.
The response to MSC treatment in these patients
has previously been reported [6,7,9] and is classified in
4 categories. Complete response to MSC treatment
was defined as loss of all symptoms of aGVHD or
HC, partial response as reduction of at least 1 grade of
GVHD or a marked reduction of transfusion need
in HC, stable disease as no worsening of symptoms,
and progressive disease as worsening of symptoms.Table 1. Patients Treated with MSCs
n 5 31
Diagnosis
Leukemia 14
Other hematologic malignancies 13
Solid tumor 2
Nonmalignant disorders 2
Disease stage (early/late) 9/18
Age median (range); child/adult 53 (1-67); 9/22
Sex (M/F) 24/7
Donors
HLA-identical related 16
HLA-identical unrelated 11
Mismatched unrelated 4
Donor age 44 (0-66)
Donor sex (M/F) 22/8
Conditioning
TBI-based MAC 5
Busulfan-based MAC 13
RIC 13
+ATG 20
GVHD prophylaxis
CsA + MTX 23
Other 8
Stem cell source (BM/PBSCs/CB) 8/21/2
NC dose (108/kg) 10.0 (0.2-28.3)
CD34 dose (106/kg) 8.3 (0.2-28.0)
Indications for MSC treatment
GVHD treatment 23
Hemorrhagic cystitis 8
MSC dose (106/kg) 1.6 (0.65-3.0)
Previous auto/allo HSCT 5/3
MSC indicates mesenchymal stroma cells; TBI, total body irradiation;
MAC, myeloablative conditioning; RIC, reduced-intensity conditioning;
ATG, antithymocyte globulin; GVHD, graft-versus-host disease; CsA,
cyclosporin; MTX, methotrexate; BM, bone marrow; PBSCs, peripheral
blood stem cells; CB, cord blood; NC, nucleated cell; HSCT, hematopoi-
etic stem cell transplantation.
Disease stage—early: nonmalignant or first remission, first chronic
phase; late: beyond these stages.Patients were judged to have responded if they had
complete or partial responses.
Ten patients received repeated MSC infusions,
because of recurring or worsening symptoms after an
initial good response in 6 cases and because of lack of
response in 4 cases.
Eight GVHD patients received other immunosup-
pressives after MSC treatment. Three nonresponding
GVHD patients with infliximab plus daclizumab, in
1 case in combination with photopheresis, 1 with
photopheresis alone because of recurring symptoms
after initial partial response, and 4 complete re-
sponders with mycophenolate mofetil or photophere-
sis (2 patients, respectively) for later chronic GVHD.
One patient with HC was treated with mycophenolate
mofetil for recurring symptoms after initial complete
response to MSC treatment.
One of the 8 HC patients was positive for adenovi-
rus in blood and urine, whereas the rest were negative
(for 1 patient, only urine analysis is available). For
BK-virus, 3 of the 4 blood samples were positive, and
5 of 5 urine samples were positive. For 2 patients, there
was no record of BK analysis.
MSCs were harvested and expanded as described
elsewhere [4,9]. Mononuclear cells were plated in
plastic culture flasks. The procedure followed good
manufacturing practice conditions according to a
common protocol devised by the developmental
committee of the European Group for Blood and
Marrow Transplantation. MSCs were derived from 23
healthy donors, with cells from each donor being used
for 1 to 5 infusions (median 2) in different patients.
The donors were 13 women and 10 men, ages from
22 to 66. The 23 patients received in total 45 MSC
transfusions. Of these transfusions, 2 were from
a HLA-identical sibling, 11 from a haplo-identical
relative and the remaining from an unrelated donor.
The patients received 1 to 5 intravenous infusions
of MSCs (median 1) expanded for a median of 3 pas-
sages (range: 1-4). The MSCs were given at a median
of 9 days (range: 0-91) after diagnosis of GVHD of
grade III (n 5 20), and at a median of 18 days (range:
11-26) after diagnosis of grade II (n 5 3).
Immunologic In Vitro Analyses
Peripheral blood mononuclear cells (PBMCs)
were taken from patients and separated by Ficoll-
Hypaque. Patient PBMCs were stimulated with an
equal number of irradiated (20 Gy) PBMCs from
a pool of 5 donors, or 10 mg/mL phytohemagglutinin
(PHA) in RPMI 1640 medium (Invitrogen, Gibco,
BRL Paisley, U.K.) supplemented with 10% heat-
inactivated human AB serum and antibiotics. Irradi-
ated (20 Gy) MSCs were added in a proportion of
10% to patient cells. Proliferation was measured on
day 6 in MLC and day 4 for PHA [4] after 24 hours
of tritium-labeled thymidine incorporation (1 mCi,
Figure 1. In vitro reactivity to MSCmeasured before and after systemic MSC treatment, with each individual compared with himself/herself. Measured
in MLC and with stimulation by PHA. No change in reactivity before and after treatment could be found.
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were harvested using a Tomtec harvesting machine
(Harvester 96, Tomtec, Orange, CT). The analysis
was made before MSC infusion (n 5 3), before and
up to 12 months after MSCs (n 5 10) or only after
MSCs (n 5 5) depending on accessibility of samples.
The MSCs used in vitro were from the same donor
as clinically given to the patient.
Levels of interleukin (IL)-6 and IL-2 receptor in
serum were analyzed on a weekly basis as a routine
procedure in all patients, using an automated chemo-
luminescence immunoassay (IMMULITE; DPC,
Los Angeles, CA). The most recent level before
MSC infusion (0-6 days) was used for comparison
with the 3 samples that followed. Soluble HLA-G1
and -G5 levels were determined by ELISA (BioVen-
dor, Modrice, Czech Republic).
Levels of soluble HLA-G (sHLA-G) were ana-
lyzed with an sHLA-G ELISA kit according to the
instructions of the manufacturer (BioVendor). Sam-
ples were incubated in microplate wells precoated
with monoclonal anti-sHLA-G.
Patient–donor chimerism was analyzed using PCR
in blood (CD19, CD3, and CD33 lineages) and bone
marrow (the same lineages plus CD34) [10]. Recipient
levels of\5% were considered full donor.Definitions and Statistics
Severe Bacteriologic Infection. Septicemia or causing
hospitalzation; bacteriologic agent identified or re-
sponding to antibiotics.
Mild Bacteriologic Infection. Local infection, not
causing hospitalization.
Severe Viral Infection. Identification of a viral agent,
causing hospitalization or organ damage.
Mild Viral Infection.Not causing hospitalization or
damage. Cytomegalovirus (CMV) [11] and Epstein-
Barr virus (EBV) were analyzed separately, where the
definition of CMV disease followed the agreed criteria
outlined by Ljungman et al. [12].Severe Fungal Infection. Fungemia or invasive.
Mild Fungal Infection. Local.
Posttransplant Lymphoproliferative Disorder (PTLD).
PAD-verified or treated.
Rejection. Increase in recipient chimerism (.95%
CD31 cells).
Causes of Death. Deaths from infections after reso-
lution of GVHD and in the absence of leukemia
relapse were counted as ‘‘deaths from infection.’’
Complications were recorded from the date of
MSC infusion.
Data were analyzed as of the last data collection in
November 2009. We estimated the probability of
survival with the Kaplan-Meier method and com-
pared it with the log-rank test (Mantel-Cox).
Transplant-related mortality was defined as death oc-
curring in the absence of relapse and summarized as
the cumulative incidence estimate with relapse as
the competing event. CMV viral load results were
transformed to log10 values, where a nominal value
of 2.3 log10 was ascribed to polymerase chain reac-
tion–negative results [13], and the peak of the first ep-
isode was compared using the Student’s t test. All
other data were analyzed using the Fisher exact test,
the Mann-Whitney U test, or, where applicable, the
paired t test.RESULTS
Immunologic Effects
There was no difference in MLC or PHA stimula-
tion before and after MSCs were given systemically to
the patient (Figure 1). We found a statistically signifi-
cant decrease in IL-2 receptor levels in blood at the first
measurement afterMSC infusion (P5 .03), which rap-
idly leveled out in the next 2 measurements (Figure 2).
There was no measureable difference in IL-6 levels
before MSC infusion (median 5.5 pg/mL; range:
1.9-49.3) and after infusion (median 7.2 pg/mL; range:
1.9-73.3).
Figure 2. Levels of IL-2 receptors in blood before and at weekly
intervals after MSC treatment. Each individual compared with himself/
herself. A significant decline in IL-2 receptors was found 1 week after
MSC treatment.
Table 2. Frequency of Infectious Complications
MSC GVHD n5 23 MSC HC n 5 8
Total
Incidence/
1000 days Total
Incidence/
1000 days
Severe bacterial infection
infection
27 2.0 8 2.8
Mild bacterial infection 19 1.4 0 0
Severe viral infection 5 0.4 3 1.0
Mild viral infection 17 1.2 8 2.8
Severe fungal infection 10 0.7 3 1.0
Mild fungal infection 7 0.5 1 0.3
EBV-activation 7 0.5 1 0.3
PTLD 2 0.1 0 0
CMV MSC GVHD n 5 19 MSC HC n 5 7
Peak (log10), mean ± 95% CI 4.1 ± 0.22 3.2 ± 0.37
CMV disease total (%) 6 (32%) 0 (0%)
MSC indicates mesenchymal stroma cells; GVHD, graft-versus-host
disease; EBV, Epstein-Barr virus; HC, hemorrhagic cystitis; PTLD, post-
transplant lymphoproliferative disorder; CMV, cytomegalovirus; CI,
confidence interval.
Table 3. Frequency of Transplantation-RelatedComplications
MSC GVHD n 5 23
(20 hem. malignancies,
2 solid tumors, 1 nonmalignant)
MSC HC n 5 8
(7 hem. malignancies,
1 nonmalignant)
Total % Total %
Relapse 2 10 0 0
Progression of
solid tumor
1 50 n/a n/a
Allograft
rejection
1 4 0 0
Chronic
GVHD
5 22 1 13
MSC indicates mesenchymal stroma cell; GVHD, graft-versus-host dis-
ease; hem, hematological; n/a, not applicable.
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MSC infusion; 14 of them were followed after MSC
treatment, and all remained full donor. One patient,
retransplanted because of previous graft rejection
with autoantibodies, had threatening graft rejection
before MSC infusion and was treated with rituximab.
She then became full donor chimera. Nine patients
were mixed chimeras before MSC treatment, in
CD3, CD33, and CD19. Two became full donor
chimeras and 6 remained mixed. In 3 patients, no chi-
merism data could be obtained. In 1 of them, leukemia
relapse was later diagnosed.
In 4 patients, s-HLA-G was below the detection
limit posttransplantation. In another 4 patients, base-
line levels were approximately 2 U/mL. In 1 patient
each, baseline levels were approximately 10, between
10 and 20, and between 10 and 50. S-HLA-G was de-
termined in 17 instances, at a median 4 (range: 1-10)
days after MSC infusion. In 3 of these instances, there
was a 3- to 6-fold increase in s-HLA-G level from
baseline. This included 1 patient with complete re-
sponse, 1 with partial response, and 1 with no response
to MSC treatment. In the other 14 cases, baseline
levels were unchanged after MSC infusion.
Incidence of bacterial, fungal, and viral disease are
shown in Table 2. CMV disease was diagnosed after
MSC treatment in 3 patients with aGVHD, which
gives an incidence of 18% when excluding seronega-
tive patients receiving seronegative grafts. All 3 cases
were of CMV colitis. Four patients were diagnosed
with CMV colitis before treatment with MSC and
are not included in the previous count. No patients
treated for HC developed CMV disease. Seropositive
patients receiving seronegative grafts showed higher
peak viral load, but this was not correlated to CMV
disease where all 7 cases were in patients receiving
seropositive grafts. Patients were treated with ganci-
klovir or valganciklovir at a viral load of 1000 copies,
according to clinical routine.Incidence of transplant-related complications
including leukemia relapse, allograft rejections, and
secondary malignancies are shown in Table 3. Two
patients had relapse of hematologic malignancies:
1 with myeloma and 1 with ALL. One patient under-
going allogeneic hematopoietic stem cell transplanta-
tion for acute myelogenous leukemia, who was treated
with MSC for aGVHD, developed Hodgkin’s lym-
phoma 3 years after having received MSC.Survival
One hundred days after development of aGVHD,
nonrelapse mortality was 26% (95% confidence inter-
val [CI]: 8%-44%) and OS was 70% (52%-88%) for
the patients treated with MSCs. Two years after
GVHD, the corresponding figures were 61% (95%
CI: 41%-81%) for nonrelapse mortality and 26%
(8%-44%) for OS. In the HC patients, 2-year survival
was 38%.
The median survival for aGVHD patients was
182 days and, for HC, 120 days after treatment with
Table 4. Causes of Death
Infection
(%)
Relapse
(%)
Acute GVHD
(%) HC (%)
Progression of Solid
Tumor (%)
Secondary
Malignancy (%)
Other
(%)
Death from
All Causes (%)
MSC GVHD (n 5 23) 7 (30%) 1 (4%) 10 (43%) n/a 0 (0%) 1 (4%)* 0 (0%) 19 (83%)
MSC HC (n 5 8) 1 (13%) 0 (0%) n/a 3 (38%) n/a 0 (0%) 1 (13%)† 5 (63%)
GVHD indicates graft-versus-host disease; HC, hemorrhagic cystitis; MSC, mesenchymal stroma cells.
*Hodgkin’s lymphoma.
†Gastrointestinal bleeding.
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GVHD group, 10 patients (43%) died from aGVHD.
Nine of the 10 were classified as nonresponders to
MSC treatment and 1 as a partial response.
Death from infection after resolved GVHD
occurred in 7 patients, which corresponds to 30% of
the entire group or 54% of the GVHD survivors.
These lethal infections occurred between 4 months
and 2 years after MSC treatment and included 3 fun-
gal infections (Aspergillus), 2 bacterial septicemia
(Escherichia coli and Staphylococcus aureus), 1 dual
infection with EBV and CMV, and 1 pneumonia of
unknown origin. Of the 7 patients who died from in-
fections, 4 had been treated with other second- or
third-line immunosuppressive agents in addition to
MSC, including infliximab, daclizumab, photophere-
sis, sirolimus, and mycophenolate mofetil.
Three patients with GVHD were still alive at
follow-up, all complete responders to MSC treatment.
Of 8 patients treated with MSCs for HC, 3 died
from multiple organ failure [7]. Two of them were
classified as partial response toMSCs and 1 as a nonre-
sponder. One patient died from respiratory syncytial
virus pneumonia following improvement of HC,
another died from gastrointestinal bleeding 5 months
after HC had resolved. In this group, there were 3
long-term survivors, all complete responders.
Prediction of Outcome
In vitro testing of immunosuppression of patient
PBMCs by MSCs, measured in MLCs or after PHA
stimulation before initiating MSC treatment, did not
correlate to clinical response (Figure 3).Figure 3. Comparison of in vitro inhibition of patient PBMCs by MSC
treatment in clinical responders and nonresponders. Measured in MLC
and with stimulation by PHA. No correlation was found between in vitro
results and clinical response.The MSC dose given did not affect response rate,
and neither did any factors concerning theMSC donor
(age, sex, related or not related to the recipient). The
response rate was better among children than adults
treated for GVHD (83% complete or partial response
compared with 44% among adults), and this could also
be seen in a significantly better survival (P5 .005). The
same tendency was seen in HC, but the group is too
small for meaningful statistics.
The number of MSC expansion passages could be
correlated to both better response and better survival
in patients treated for aGVHD. Patients who received
first-passage (n5 1) or second-passageMSC (n5 7) at
any time as treatment for aGVHDhad a 1-year survival
of 75% (95% CI: 46%-100%) compared with 21%
(0%-42%) in 14 patients given only MSCs from
passages 3-4 (P5 .01) (Figure 4).Therewere 4 children
in the early MSC passage group, as opposed to 2 in the
3-4 passage group, but survival was still significantly
better when excluding children from the analysis
(at 1 year: 50% versus 8%, P 5 .02). It correlates well
with both response rate (86% complete response in
the early passage group, 36% complete and partial
response in the late passage group) and with cause
of death (only 1 patient who received early-passage
MSCs died of GVHD as opposed to 9 of 14 who re-
ceived late passage).
There was no correlation between choice of immu-
nosuppressive agent before initiation of MSC treat-
ment and response to MSCs.
Of the 4 patients with CMV colitis before MSC
treatment, 3 showed no response to MSCs, and the
median survival was only 53 days. For the patients
with CMV disease after MSC treatment, however,Figure 4. OS in GVHD patients treated with MSCs from both early
passage (1-2) and late passage (3-4) (P\.01).
562 Biol Blood Marrow Transplant 18:557-564, 2012L. von Bahr et al.the survival was similar to the rest of the group
(182 days).DISCUSSION
We have previously shown a difference in outcome
in patients who respond to MSC treatment and those
who do not respond [9]. Because only one-half of the
patients treated with MSCs for therapy-resistant
aGVHD have a complete response, it is important to
be able to predict responsiveness. We therefore tested
in vitro whether the inhibitory capacity of MSCs in
MLC and mitogenic responses to PHA were corre-
lated with clinical effects of the same MSCs when
given to the patients (Figure 3). These in vitro analyses
did not correspond with the response in vivo and are
evidently not useful.
High levels of IL-2 receptor in blood are a bio-
chemical indicator of aGVHD [14]. The pattern after
MSC infusion—with a fall within days, which then
levels out over the next few weeks—may indicate an
immediate immunosuppressive effect of MSCs.
MSCs produce high levels of IL-6 [15], but no change
in IL-6 levels was seen in the patients. We conclude
that any such production of IL-6 by MSCs given to
patients was too low to be detectable in serum.
There was no difference in patient lymphocyte
response in MLCs or to PHA in vitro before and after
MSC infusion. This may indicate that MSCs do not
affect immune responsiveness in circulating lympho-
cytes. However, it should be noted that all these
patients are treated with high-dose steroids, which
have a profound effect on immune function in hemato-
poietic stem cell transplant recipients [16]. They
were also treated with cyclosporine, but this does not
affect lymphocyte response in vitro, unless present in
the medium.
This suggests that MSCs do not have a systemic
effect on circulating immune reactive cells, but stillmay
exert local effects in inflamed or damaged tissues—
either by being directly immune-suppressive and
anti-inflammatory, or as a bystander by triggering
other cell types [15]. MSCs have been reported to tar-
get damaged tissue [6,7,17,18]. After redistribution of
MSCs to the lungs and then to the liver and spleen,
the cells are no longer detectable. Thus, major
systemic effects on circulating immune cells and
cytokines should not be expected.
HLA-G secretion by MSCs has been 1 of the pro-
posed suppressive mechanisms [19,20]. In the present
analysis, HLA-G levels in serum increased after 3 of
17 MSC infusions. In organ transplant recipients, an
increase in HLA-G was reported to correlate with
allograft acceptance [21,22]. In our patients, HLA-G
levels remained stable posttransplantation in 14 of
the 17 cases. At least in serum, HLA-G levels did not
correlate with response to MSCs.Because the patients presented in this study repre-
sent the majority of patients with steroid-refractory
GVHD in our center during this time, we have not
been able to find a good enough matching control
group. Because of this, we have chosen to present the
complications in a purely descriptive way. For efficacy
and more comparable safety data, we await the results
of an ongoing, multicenter randomized study compar-
ing MSC treatment to placebo.
CMV peak viral load was higher than we expected.
This appears to contradict a previous in vitro study,
which showed that cytotoxic T cells against CMV
were not affected by MSCs, in contrast to alloreactive
T cells [5]. Incidence of CMV disease was very high in
the MSC-treated GVHD patients, but it should be
noted that all cases were in the GVHD-affected organ
(colitis) and most cases were classified as mild. That
the patients were a high-risk group for developing
CMV disease can be seen by the fact that there were
4 more cases of CMV disease (all colitis), which were
diagnosed before MSC treatment began and not in-
cluded in the previous count. The patient material
was too limited for more advanced statistical compar-
isons.
We find it worth noting that in patients suffering
fromCMV colitis beforeMSC treatment, the response
is poor.
There is a clinical association between CMV and
severe aGVHD. CMV may trigger aGVHD and vice
versa [23]. This has also been demonstrated in a mouse
model, where GVHD reactions were augmented by
CMV [24].
The infection-related mortality remained high
for a long period after resolution of GVHD. This
may reflect a prolonged immunosuppressive effect of
MSCs, but may also be related to the pronounced
immunosuppressive effect of severe GVHD [16].
Our patients followed a standard protocol, which
did not include antifungal or antiviral prophylaxis.
Of the 13 patients who recovered from GVHD after
treatment with MSCs, 7 died later from infections.
This indicates the need for prolonged antifungal pro-
phylaxis and close monitoring of these patients.
A previous study showed that MSCs given at the
time of transplantation to enhance engraftment in-
creased the risk of leukemic relapse [8]. Because of
the antileukemic effect of GVHD, the risk of leukemic
relapse in these patients may not be high, and we only
saw 2 cases of relapse after MSC treatment among the
27 patients with hematologic malignancies: 1 patient
having myeloma and 1 acute lymphocytic leukemia
with minimal residual disease diagnosed in flow cy-
tometry shortly before death in Aspergillus pneumonia.
Thus, in these patients, there was no indication that
MSCs abrogate the graft-versus-leukemia effect.
An interesting finding was that patients treated
with MSCs from first or second passage had a better
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MSCs (Figure 4). It is based on few observations,
but the difference is striking. Because MSCs from
the same donor have been given to several patients,
in 6 cases at different passages, we have also been
able to analyze this in individual MSC batches. The
same pattern with better response and longer survival
in early passage can be seen in 5 of these 6 cases. In
the remaining case, the response does not differ be-
tween the 2 infusions, which were given for HC.
However, it should be noted that the effect of
passage is only seen in vivo and not in vitro. We stud-
ied the immunomodulatory effects of MSCs from
passage 2 to passage 7 and there was no difference in
inhibitory capacity in MLC [25]. On the other hand,
early experimental results indicate a change in MSC
surface structures with increasing passage, possibly
affecting MSC functionality (unpublished).
Culture of MSCs for at least 2 passages has been
recommended to obtain cell purity. Before infusion,
cells were analyzed with flow cytometry and found
positive for MSC markers CD166, CD105, CD73,
CD44, and CD29, as well as negative for markers for
hematopoietic cells (CD14, CD45, and CD34). How-
ever, prolonged culture periods may impair MSC
function and attenuate the anti-inflammatory effect
of early-passage MSCs. Meanwhile, leukocytes surviv-
ing the first or second passage do not appear to induce
immune reactions in mismatched recipients. Thus,
purity may be of less importance than previously
expected. Further studies are needed to support or
refute the role of passage.
BecauseMSCs seem safe with regard to relapse and
graft rejection, it appears justified to use it at an earlier
stage while providing vigilant surveillance for infec-
tious complications. Hopefully, this will improve the
response rate regarding toxic side effects as well as
GVHD.
In conclusion, MSC treatment for aGVHD is
relatively safe, but infections remain a major risk long
after GVHD has resolved. Long-term survival may
be improved by monitoring infections, antifungal pro-
phylaxis, and possibly by using early-passage MSCs.ACKNOWLEDGMENTS
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